Dynamical coupled channel calculation of pion and omega meson production

A dynamical coupled channel approach is used to study $\pi$ and $\omega$--meson production induced by pions and photons scattering from the proton. Six intermediate channels including $\pi N$, $\eta N$, $\pi\Delta$, $\sigma N$, $\rho N$ and $\omega N$ are employed to describe unpolarized and polarized data. Bare parameters in an effective hadronic Lagrangian are determined in a fit to data for $\pi N \to \pi N$, $\gamma N \to \pi N$, $\pi^- p \to \omega n$, and $\gamma p \to \omega p$ reactions at center-of-mass energies from threshold to $W < 2.0$ GeV. The $T$ matrix determined in these fits is used to calculate the photon beam asymmetry for $\omega$-meson production and the $\omega N \to\omega N$ total cross section and $\omega N$ scattering lengths.Comment: 26 pages, 18 figures, submitted to Phys. Rev. C; corrected typos, added references, minor revisions, same results/fig

Backward-angle photoproduction of π0\pi^0 mesons on the proton at EγE_\gamma = 1.5--2.4 GeV

Differential cross sections and photon beam asymmetries for $\pi^0$ photoproduction have been measured at $E_\gamma$ = 1.5--2.4 GeV and at the $\pi^0$ scattering angles, --1 $<$ cos$\Theta_{c.m.} <$ --0.6. The energy-dependent slope of differential cross sections for $u$-channel $\pi^0$ production has been determined. An enhancement at backward angles is found above $E_\gamma$ = 2.0 GeV. This is inferred to be due to the $u$-channel contribution and/or resonances. Photon beam asymmetries have been obtained for the first time at backward angles. A strong angular dependence has been found at $E_\gamma >$ 2.0 GeV, which may be due to the unknown high-mass resonances.Comment: 12 pages, 4 figures, submitted to PL

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection

BACKGROUND Clostridium difficile is the most common cause of infectious diarrhea in hospitalized patients. Recurrences are common after antibiotic therapy. Actoxumab and bezlotoxumab are human monoclonal antibodies against C. difficile toxins A and B, respectively. METHODS We conducted two double-blind, randomized, placebo-controlled, phase 3 trials, MODIFY I and MODIFY II, involving 2655 adults receiving oral standard-of-care antibiotics for primary or recurrent C. difficile infection. Participants received an infusion of bezlotoxumab (10 mg per kilogram of body weight), actoxumab plus bezlotoxumab (10 mg per kilogram each), or placebo; actoxumab alone (10 mg per kilogram) was given in MODIFY I but discontinued after a planned interim analysis. The primary end point was recurrent infection (new episode after initial clinical cure) within 12 weeks after infusion in the modified intention-to-treat population. RESULTS In both trials, the rate of recurrent C. difficile infection was significantly lower with bezlotoxumab alone than with placebo (MODIFY I: 17% [67 of 386] vs. 28% [109 of 395]; adjusted difference, −10.1 percentage points; 95% confidence interval [CI], −15.9 to −4.3; P<0.001; MODIFY II: 16% [62 of 395] vs. 26% [97 of 378]; adjusted difference, −9.9 percentage points; 95% CI, −15.5 to −4.3; P<0.001) and was significantly lower with actoxumab plus bezlotoxumab than with placebo (MODIFY I: 16% [61 of 383] vs. 28% [109 of 395]; adjusted difference, −11.6 percentage points; 95% CI, −17.4 to −5.9; P<0.001; MODIFY II: 15% [58 of 390] vs. 26% [97 of 378]; adjusted difference, −10.7 percentage points; 95% CI, −16.4 to −5.1; P<0.001). In prespecified subgroup analyses (combined data set), rates of recurrent infection were lower in both groups that received bezlotoxumab than in the placebo group in subpopulations at high risk for recurrent infection or for an adverse outcome. The rates of initial clinical cure were 80% with bezlotoxumab alone, 73% with actoxumab plus bezlotoxumab, and 80% with placebo; the rates of sustained cure (initial clinical cure without recurrent infection in 12 weeks) were 64%, 58%, and 54%, respectively. The rates of adverse events were similar among these groups; the most common events were diarrhea and nausea. CONCLUSIONS Among participants receiving antibiotic treatment for primary or recurrent C. difficile infection, bezlotoxumab was associated with a substantially lower rate of recurrent infection than placebo and had a safety profile similar to that of placebo. The addition of actoxumab did not improve efficacy. (Funded by Merck; MODIFY I and MODIFY II ClinicalTrials.gov numbers, NCT01241552 and NCT01513239.

an association between diversity and exoticism

Focusing on contemporary Iranian artists and intellectuals, I examine the creation of collective identifications from an internal perspective. Drawing on research on migrant associations and ethnic and racial boundaries in Germany, the ethnographic account alternates between internal relations, member's participation in the transnational field of Iranian artists, and representative activities in the German public sphere. It explains how the members' unequal resources and varying politics of value caused a shift in the association's system of value. From a critique of assimilationism and the promotion of the value of diversity, the group came to largely comply with the system of value prevailing in the German public sphere, sustained by its intersection with the one that shapes the transnational social field of Iranian artists

Beam asymmetry Σ for π+ and π0 photoproduction on the proton for photon energies from 1.102 to 1.862 GeV

Beam asymmetries for the reactions gamma p -> p pi0 and gamma p -> n pi+ have been measured with the CEBAF Large Acceptance Spectrometer (CLAS) and a tagged, linearly polarized photon beam with energies from 1.102 to 1.862 GeV. A Fourier moment technique for extracting beam asymmetries from experimental data is described. The results reported here possess greater precision and finer energy resolution than previous measurements. Our data for both pion reactions appear to favor the SAID and Bonn-Gatchina scattering analyses over the older Mainz MAID predictions. After incorporating the present set of beam asymmetries into the world database, exploratory fits made with the SAID analysis indicate that the largest changes from previous fits are for properties of the Delta(1700) 3/2- and Delta(1905) 5/2+ states.Comment: 24 pages 20 figure

Circadian Clocks as Modulators of Metabolic Comorbidity in Psychiatric Disorders

Psychiatric disorders such as schizophrenia, bipolar disorder, and major depressive disorder are often accompanied by metabolic dysfunction symptoms, including obesity and diabetes. Since the circadian system controls important brain systems that regulate affective, cognitive, and metabolic functions, and neuropsychiatric and metabolic diseases are often correlated with disturbances of circadian rhythms, we hypothesize that dysregulation of circadian clocks plays a central role in metabolic comorbidity in psychiatric disorders. In this review paper, we highlight the role of circadian clocks in glucocorticoid, dopamine, and orexin/melanin-concentrating hormone systems and describe how a dysfunction of these clocks may contribute to the simultaneous development of psychiatric and metabolic symptoms